Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279175 | 0.86 | KMT2A (0.47) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL676909 | 0.85 | KMT2A (0.58) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL279599 | 0.79 | KMT2A (0.48) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL279173 | 0.79 | KMT2A (0.48) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL463663 | 0.79 | LMNA (0.59) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL6936328 | 0.79 | MMP2 (0.55) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL8779173 | 0.79 | KMT2A (0.52) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL697317 | 0.79 | CA1 (0.56) | KMT2AMEN1ALDH1A1LMNAHTT | |
| SCHEMBL13969403 | 0.77 | RAB9A (0.41) | KMT2AMEN1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL8830906 | 0.77 | KMT2A (0.50) | KMT2AMEN1ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309300-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8197847-B2 | Process for making polymers and supports comprising pendant sugar side groups | WARWICK EFFECT POLYMERS LTD. (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110137017-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | EIGENBROT CHARLES W | 2011-06-09 | — | — | US | disclosed |
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7855275-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100003766-A1 | screening cysteine engineered antibodies for thiol reactivity; using antibodies or antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor or cancer cells | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7521541-B2 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENETECH INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090082224-A1 | POLYMERS | WARWICK EFFECT POLYMERS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| US-20080300348-A1 | Polymer | WARWICK EFFECT POLYMERS LIMITED | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137017-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | LNPEP, ALB, GSTP1 | KMT2A 3588/4885MEN1 4739/4885ALDH1A1 382/4885 |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | ALB, LNPEP, CSTB | KMT2A 3830/4885MEN1 3930/4885ALDH1A1 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.